Vision Biotechnology Türkiye
An operating manufacturing facility supporting medical-plastics, rapid-test, PCR-test, FIA-test and diagnostic-device production.
What is publicly disclosed.
An operating manufacturing facility supporting medical-plastics, rapid-test, PCR-test, FIA-test and diagnostic-device production.
The project is classified as Medical and diagnostic manufacturing facility. Its public status is Completed, and the published location is Türkiye. Where the disclosed area is available, it is stated as 4,000 m²; this value is not converted into a cleanroom, operating or ownership claim.
Scope is separated by work package.
- Medical-plastics production
- Lateral-flow rapid-test production
- PCR-test production
- FIA-test production
- Diagnostic-device production
Each item describes the disclosed engagement boundary. It does not imply services outside the listed scope or transfer responsibility from the client, operator, technology owner or competent authority.
Evidence follows the Seven-Gate Framework.
Reference evidence is assessed against investment definition, concept design, engineering, procurement and technology integration, quality readiness, commissioning and operational handover. The applicable gates depend on the contracted work packages. A design-only engagement is not presented as construction; equipment supply is not presented as complete EPC.
Review the Seven-Gate Framework ↗What this page does not claim.
The published area is gross facility area. It is not presented as cleanroom area or as Infinity-owned space.
Certification, accreditation, product registration and market authorisation remain subject to independent competent authorities and the accountable legal entity. Commercial values, restricted drawings, capacities and client documentation are released only where authorised or during qualified due diligence under NDA.
Connect the reference to an investable project scope.
The reference demonstrates a disclosed technical engagement, not a generic promise of identical cost, capacity or schedule elsewhere. A new programme must be sized for destination-market demand, utilities, workforce, regulatory pathway, site conditions and intended operating model.